Edwards Lifesciences (EW) Updates Q1 Earnings Guidance

This was up from $163.6 million, or $0.75 per share, in last year's fourth quarter.

The stock decreased 0.43% or $0.05 during the last trading session, reaching $11.65. About 280,914 shares traded. Cheniere Energy, Inc. (NYSEAMERICAN:LNG) has risen 51.31% since February 2, 2017 and is uptrending. It has underperformed by 24.43% the S&P500. Canaccord Genuity reiterated a "buy" rating and issued a $174.00 price target (up previously from $140.00) on shares of Edwards Lifesciences in a report on Friday.

Edwards Lifesciences announced that its board has initiated a share buyback program on Thursday, December 7th that permits the company to repurchase $1.00 billion in outstanding shares. If the $145.80 price target is reached, the company will be worth $2.29B more. ING Groep NV now owns 22,905 shares of the medical research company's stock valued at $2,504,000 after acquiring an additional 6,684 shares in the last quarter.

To gain some better insight into how Edwards Lifesciences Corporation (NYSE:EW) is performing, let's look at some of the company's recent insider trading activity. It has underperformed by 1.29% the S&P500.

Hawaii transfer Dru Brown chooses OSU
Brown announced he was leaving Hawaii in January as a grad transfer and going to the Cowboys program is a good fit for him. At Hawaii, Brown passed for 5,277 yards, 37 touchdowns, 15 interceptions and completed a solid 62 percent of his passes.

Financial Engines Advisors L.L.C. grew its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 57.6% during the fourth quarter, HoldingsChannel.com reports. Therefore 75% are positive. Edwards Lifesciences has a one year low of $88.67 and a one year high of $138.48. $124.71's average target is -9.68% below currents $138.07 stock price. The company's revenue was up 15.7% compared to the same quarter last year. sell-side analysts predict that Edwards Lifesciences will post 3.76 earnings per share for the current fiscal year. As per Friday, May 26, the company rating was maintained by Jefferies. The firm has "Outperform" rating by Credit Suisse given on Monday, August 10. The firm has "Buy" rating given on Thursday, July 27 by Bank of America. The rating was maintained by Stephens on Wednesday, August 26 with "Overweight". Canaccord Genuity restated a "buy" rating and set a $155.00 target price on shares of Edwards Lifesciences in a research note on Sunday, October 8th. Edwards Lifesciences now has a consensus rating of "Buy" and a consensus target price of $131.98. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock.

The most recent open market insider trade was Automatic Sell of 5,300 shares on a day where the closing price was 127.22.

Analysts expect Edwards Lifesciences Corporation (NYSE:EW) to report $0.90 EPS on February, 7.They anticipate $0.15 EPS change or 20.00% from last quarter's $0.75 EPS. -Earnings Growth (Y-o-Y): 24.1% -EPS (Q4): $0.94 vs. $0.75 a year ago. EW's profit would be $190.46M giving it 35.27 P/E if the $0.90 EPS is correct.

TRADEMARK VIOLATION NOTICE: "Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Edwards Lifesciences (NYSE:EW) Share Price" was first published by The Lincolnian Online and is the property of of The Lincolnian Online.

Saudi contributes 2 bln United States dollars to Yemen
Some 279 civilians died as a result of Saudi Arabia-led coalition airstrikes, in addition to the 121 killed by Iranian-backed Houthi fighters, the report noted.

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and fix products used to replace or fix a patient's diseased or defective heart valve. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 38.57 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and fix products, which are used to replace or fix a patientÂ's diseased or defective heart valve.

Investors sentiment decreased to 1.36 in Q3 2017. Its down 1.00, from 1.33 in 2017Q2. It is positive, as 18 investors sold STOR shares while 70 reduced holdings. 30 funds opened positions while 48 raised stakes.

Several analysts have issued reports on EW shares. Granahan Invest Mngmt Incorporated Ma holds 0.15% or 61,520 shares in its portfolio. Thrivent Finance For Lutherans, Minnesota-based fund reported 86,054 shares.

Cheniere Energy Incorporated (NYSEAMERICAN:LNG) had an increase of 2.68% in short interest. (NYSEAMERICAN:LNG). Gsa Prns Ltd Liability Partnership invested in 0.04% or 12,457 shares. The Illinois-based Blair William And Il has invested 0.02% in Pool Corporation (NASDAQ:POOL). Public Sector Pension Investment Board holds 28,485 shares or 0% of its portfolio. Teacher Retirement Sys Of Texas owns 249,495 shares or 0.04% of their United States portfolio. Riverbridge Ltd Liability Co accumulated 2.80 million shares. Virginia Retirement Et Al holds 0.16% or 544,500 shares in its portfolio.

Liposuction Devices Market: Sales, Ex-factory Price, Revenue, Gross Margin Analysis 2017
An up-to-date research has been disclosed by Questale highlighting the Global Invasive Hemodynamic Monitoring Devices segment . Chapter 2 analyses Hyperbaric Oxygen Therapy Devices industry scenario, the major participant, and their global market share.

The Irvine, Calif. -based company posted sales of $35.7 million, or 17¢ per share, on sales of $888.5 million for the 3 months ended December 31, seeing the bottom line shrink 77.5% while sales grew 15.7% compared with the same period during the previous year.

Latest News